Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
ACET Total Liabilities
Everything the company owes to creditors and other parties.
Adicet Bio, Inc.NASDAQ: ACET
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $29.32M at the end of Q1 FY2026, down 1.7% from a year earlier and down 11.5% from the prior quarter. Over 3 fiscal years it compounded at -4.7% a year.
Context
- Total liabilities amounted to 17.3% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -1.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 33.15M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- -1.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.15M | -1.4% |
| FY2024 | 2024-12-31 | 33.61M | -9.5% |
| FY2023 | 2023-12-31 | 37.12M | -3.2% |
| FY2022 | 2022-12-31 | 38.35M | +7.1% |
| FY2021 | 2021-12-31 | 35.81M | — |
Total Liabilities vs competitors
How ACET compares with its peers on the latest reported figures
- ACET's Mar 2026 total liabilities of $29.32M is the 4th highest of the 8 companies compared; the peer median is $25.72M.
- Its year-over-year change of -1.7% is the 3rd highest of 8, against a peer median of -19.0%.
- Total liabilities amounts to 17.3% of total assets for ACET, versus a peer median of 32.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $105.07M | -14.2% | +2.0% | 52.0% | |
| Dec 2025 | $42.91M | +10.8% | -14.8% | 54.8% | |
| Mar 2026 | $38.51M | +49.2% | +29.7% | 20.3% | |
| Mar 2026 | $29.32M | -1.7% | -4.7% | 17.3% | |
| Mar 2026 | $25.72M | -21.5% | +16.2% | 216.1% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $12.32M | -22.8% | +17.0% | 11.4% |
| Jun 2026 | $7.86M | -84.6% | +5.6% | 32.6% | |
| Mar 2026 | $4.73M | -19.0% | -6.6% | 25.3% | |
| Peer median (excluding ACET) | $25.72M | -19.0% | +5.6% | 32.6% | |
Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 277.54M | 257.66M | 159.71M | 56.5M | 38.92M |
| Short-term Investments | 0 | 0 | 0 | 119.81M | 119.61M |
| Net Receivables | 214K | 435K | 0 | 0 | 342K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2K | 336K | 457K | 474K | 320K |
| Total Current Assets | 282.44M | 261.04M | 162.27M | 180.14M | 160.93M |
| Property, Plant & Equipment (Net) | 35M | 48.98M | 44.2M | 36.75M | 28.48M |
| Goodwill | 19.46M | 19.46M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.87M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.04M | 1.21M | 822K | 3.33M | 76K |
| Total Non-current Assets | 56.5M | 69.65M | 45.02M | 40.08M | 31.43M |
| Total Assets | 338.94M | 330.69M | 207.3M | 220.22M | 192.36M |
| Account Payables | 3.26M | 4.4M | 2.63M | 4.83M | 4.74M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.81M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.02M | 5.7M | 6.93M | 7.11M | 5.63M |
| Total Current Liabilities | 16.32M | 19.71M | 19.29M | 19.39M | 21.53M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 115K | 114K | 130K | 116K | 62K |
| Total Non-current Liabilities | 19.49M | 18.65M | 17.83M | 14.22M | 11.61M |
| Total Liabilities | 35.81M | 38.35M | 37.12M | 33.61M | 33.15M |
| Common Stock | 4K | 4K | 4K | 8K | 10K |
| Retained Earnings | (168.32M) | (238.11M) | (380.77M) | (497.89M) | (614.7M) |
| Accumulated OCI | 0 | 0 | 0 | 16K | 102K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 303.13M | 292.34M | 170.18M | 186.61M | 159.21M |
| Total Debt | 20.94M | 21.02M | 20.92M | 17.23M | 14.74M |
| Net Debt | (256.6M) | (236.63M) | (138.79M) | (39.26M) | (24.18M) |
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.